Crouse, Bethany http://orcid.org/0000-0002-1984-2465
Robinson, Christine
Huseby Kelcher, April http://orcid.org/0000-0002-9665-2921
Laudenbach, Megan
Abrahante, Juan E. http://orcid.org/0000-0002-9074-4307
Pravetoni, Marco http://orcid.org/0000-0003-1036-0184
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA041730, T32DA007097, T32DA037183, T32DA007097, T32DA037183)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 19 May 2020
Accepted: 10 September 2020
First Online: 21 October 2020
Competing interests
: M.P. is the inventor of “Cytokine Signaling Immunomodulators and Methods”, and “fentanyl hapten-conjugates and methods for making and using same” patents. The anti-IL-13 mAb was obtained from Genentech under a standard Material Transfer Agreement. All authors declare that there are no other competing interests.